You have 9 free searches left this month | to do more

duvelisib

Duvelisib is a drug used to treat Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma, and other conditions. Duvelisib is being actively studied in 19 studies and prior, has been studied in 4.

Top SponsorsTop SitesTop Investigators
SecuraBioWashington University School of MedicineEdmund Waller
Washington University School of MedicineDana Farber Cancer InstituteClare Sun, M.D.
AbbVieMemorial Sloan Kettering Cancer CenterDavid Bond, MD
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
W
Active, not recruiting
  • COVID-19
  • Duvelisib
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
2022-02-21
Feb 21, 2022
H
Recruiting
  • Non Hodgkin Lymphoma
  • +3 more
  • Tampa, Florida
    Moffitt Cancer Center
2022-03-14
Mar 14, 2022
W
Recruiting
  • T-Cell Lymphoma
  • Duvelisib
  • Peripheral blood draw
  • Saint Louis, Missouri
    Washington University School of Medicine
2022-03-17
Mar 17, 2022
W
Recruiting
  • Non-hodgkin Lymphoma
  • Acute Lymphocytic Leukemia
  • Duvelisib
  • Saint Louis, Missouri
    Washington University School of Medicine
2022-03-01
Mar 1, 2022
N
Terminated
  • Small Lymphocytic Leukemia (SLL)
  • Chronic Lymphocytic Leukemia (CLL)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-02-15
Feb 15, 2022
E
Completed
  • COVID-19
  • Duvelisib
  • Placebo
  • Atlanta, Georgia
  • +2 more
2022-03-10
Mar 10, 2022
J
Recruiting
  • Unresectable Melanoma
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
2021-08-10
Aug 10, 2021
G
Recruiting
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • +4 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2022-02-07
Feb 7, 2022
N
Not yet recruiting
  • Adult T-cell Leukemia/Lymphoma
  • +4 more
  • CC-486 (5-azacitidine)
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
C
Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Duvelisib
  • Duarte, California
  • +2 more
2021-08-13
Aug 13, 2021
N
Recruiting
  • Recurrent Follicular Lymphoma
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-12-16
Dec 16, 2021
E
Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Duvelisib
  • Tisagenlecleucel
  • Atlanta, Georgia
  • +1 more
2022-02-21
Feb 21, 2022
C
Unknown status
  • Follicular Lymphoma
  • Duvelisib
  • Shanghai, Shanghai, China
    Shanghai Ruijin Hospital
2021-01-10
Jan 10, 2021
S
Suspended
  • Head and Neck Squamous Cell Carcinoma
  • duvelisib
  • pembrolizumab
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
2021-03-15
Mar 15, 2021
S
Terminated
  • Follicular Lymphoma
  • Duvelisib
  • +2 more
  • Frankston, Victoria, Australia
  • +4 more
2021-03-15
Mar 15, 2021
S
Withdrawn
  • Lymphoma
  • Duvelisib
  • +3 more
  • Miami, Florida
    (unnamed)
2021-03-15
Mar 15, 2021
D
Recruiting
  • Chronic Lymphocytic Leukemia
  • Richter Syndrome
  • Miami, Florida
  • +6 more
2021-11-22
Nov 22, 2021
M
Recruiting
  • T-cell Lymphomas
  • NK-Cell Lymphomas
  • Basking Ridge, New Jersey
  • +6 more
2022-01-03
Jan 3, 2022
S
Active, not recruiting
  • Peripheral T-cell Lymphoma
  • Duvelisib
  • Duarte, California
  • +27 more
2022-01-25
Jan 25, 2022
M
Active, not recruiting
  • Lymphoma
  • Relapsed/Refractory T-cell Lymphomas
  • Stanford, California
  • +10 more
2022-02-23
Feb 23, 2022
D
Recruiting
  • Chronic Lymphocytic Leukemia
  • +7 more
  • Duvelisib
  • Nivolumab
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-01-26
Jan 26, 2021
S
Withdrawn
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Duvelisib
  • Tempe, Arizona
  • +7 more
2021-03-15
Mar 15, 2021
S
Terminated
  • CD20+ Follicular Lymphoma
  • Duvelisib
  • +2 more
  • Los Angeles, California
  • +20 more
2021-03-15
Mar 15, 2021